Barosmin against postprandial hyperglycemia: outputs from computational prediction to functional responses in vitro.

Previously, barosmin has been demonstrated to possess anti-diabetic action. However, its effect to inhibit -amylase and -glucosidase, including glucose utilization efficacy, has yet to be revealed. Hence, the current study attempted to assess the efficiency of barosmin in inhibiting the -amylase, -glucosidase, and dipeptidyl peptidase 4 enzymes, including glucose uptake efficacy.